Table VI.
Previous reports of clinical outcomes in patients with metastatic colorectal cancer treated with trifluridine/tipiracil plus bevacizumab as a late-line treatment.
| Author, year (ref.) | Number of patients | RR, % | DCR, % | PFS, months | OS, months | Grade 3 or 4 neutropenia in all treatment periods, % |
|---|---|---|---|---|---|---|
| Kuboki et al, 2017 (11) | 21 | 0.0 | 64.0 | 3.7 | 11.4 | 72.0 |
| Kotani et al, 2019 (17) | 60 | 5.0 | 53.3 | 3.7 | 8.6 | 50.0 |
| Matsuhashi et al, 2019 (18) | 17 | 0.0 | 70.1 | 6.8 | 14.1 | 41.2 |
| Pfeiffer et al, 2020 (14) | 46 | 2.2 | 67.4 | 4.6 | 9.4 | 67.4 |
| Fujii et al, 2020 (19) | 21 | 0.0 | 76.1 | 5.6 (TTF) | 14.4 | 52.4 |
| Shibutani et al, 2020 (20) | 36 | 8.3 | 58.3 | – | – | 38.9 |
| Nose et al, 2020 (16) | 32 | – | – | 4.7 | 11.7 | 53.1 |
| Data in present study | 94 | 0.0 | 44.7 | 2.9 | 10.0 | 51.1 |
RR, response rate; DCR, disease control rate; PFS, progression-free survival; OS, overall survival; TTF, time to treatment failure; -, not available.